MFDS — authorised 25 November 2019
- Marketing authorisation holder: GLOBAL BLOOD THERAPEUTICS INC
- Status: likely_approved
🇰🇷 Oxbryta in South Korea
MFDS authorised Oxbryta on 25 November 2019
Marketing authorisation
Oxbryta in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in South Korea
Frequently asked questions
Is Oxbryta approved in South Korea?
Yes. MFDS authorised it on 25 November 2019.
Who is the marketing authorisation holder for Oxbryta in South Korea?
GLOBAL BLOOD THERAPEUTICS INC holds the South Korean marketing authorisation.